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ABSTRACT
Objective We compared the effectiveness of abatacept
(ABA) versus a subsequent anti-tumour necrosis factor
inhibitor (anti-TNF) in rheumatoid arthritis (RA) patients
with prior anti-TNF use.
Methods We identiﬁed RA patients from a large
observational US cohort (2/1/2000–8/7/2011) who had
discontinued at least one anti-TNF and initiated either
ABA or a subsequent anti-TNF. Using propensity score
(PS) matching (n:1 match), effectiveness was measured
at 6 and 12 months after initiation based on mean
change in Clinical Disease Activity Index (CDAI),
modiﬁed American College of Rheumatology (mACR) 20,
50 and 70 responses, modiﬁed Health Assessment
Questionnaire (mHAQ) and CDAI remission in adjusted
regression models.
Results The PS-matched groups included 431 ABA and
746 anti-TNF users at 6 months and 311 ABA and 493
anti-TNF users at 12 months. In adjusted analyses
comparing response following treatment with ABA and
anti-TNF, the difference in weighted mean change in
CDAI (range 6–8) at 6 months (0.46, 95% CI −0.82 to
1.73) and 12 months was similar (−1.64, 95% CI
−3.47 to 0.19). The mACR20 responses were similar at
6 (28–32%, p=0.73) and 12 months (35–37%,
p=0.48) as were the mACR50 and mACR70 (12 months:
20–22%, p=0.25 and 10–12%, p=0.49, respectively).
Meaningful change in mHAQ was similar at 6 and
12 months (30–33%, p=0.41 and 29–30%, p=0.39,
respectively) as was CDAI remission rates (9–10%,
p=0.42 and 12–13%, p=0.91, respectively).
Conclusions RA patients with prior anti-TNF exposures
had similar outcomes if they switched to a new anti-TNF
as compared with initiation of ABA.
INTRODUCTION
Rheumatoid arthritis (RA) affects an estimated 1.3
million Americans and is associated with substantial
morbidity and mortality.1 To prevent the develop-
ment of permanent joint damage and deformity as
well as functional impairment, the current treat-
ment paradigm is to treat patients with active
disease with disease modifying antirheumatic drugs
(DMARDs).2 The typical approach is to introduce
a conventional non-biologic DMARD ﬁrst, fol-
lowed by combination non-biologic DMARDs
or biologics in non-responders.3 The initial
biologic used in the vast majority of patients is the
anti-tumour necrosis factor (anti-TNF). These
agents were the ﬁrst class of biologics approved by
the Food and Drug Administration (FDA) for the
treatment of RA.
However, little is known regarding what to do
when patients have an inadequate response to the
ﬁrst anti-TNF agent. Changing mechanism of
action has been shown to be beneﬁcial in compari-
sons of rituximab versus a subsequent anti-TNF4–7
as demonstrated by improvements in disease activ-
ity as well as persistence of therapy. But it is
unclear whether any change in mechanism of
action will result in improvement or if the results
seen were related speciﬁcally to B cell depletion.
Further exploration is needed to assess whether
switching to abatacept (ABA), as a different
example of changing mechanism of action, also
provides a beneﬁt among those with inadequate
response to an anti-TNF. To date, there have been
no randomised controlled trials (RCTs) comparing
the effectiveness of switching to ABA as compared
with a subsequent anti-TNF, and a recent
meta-analysis using indirect methods suggested that
use of an anti-TNF was associated with a higher
probably of achieving an American College of
Rheumatology (ACR) 50 response than ABA,
although not all indirect comparisons have shown a
difference between ABA and anti-TNF agents.8–10
In biologic-naïve patients, a few studies have com-
pared responses to ABA versus an anti-TNF.11–14 A
similar efﬁcacy was found when comparing
responses to ABA and inﬂiximab, although there
have been concerns that the results may not be gen-
eralisable to the US population of RA patients due
to the lower doses of inﬂiximab used (3 mg/kg
every 8 weeks) and lack of the usual inﬂiximab
loading dose. Additionally, ABA (in combination
with methotrexate (MTX)) has been compared
with adalimumab with MTX among biologic-naïve
RA patients with similar ACR response rates.14
Given the absence of head-to-head RCTs addres-
sing best treatment approaches in patients with
inadequate response to an anti-TNF agent, com-
parative effectiveness studies using observational
data from registries can be employed.15 Therefore,
the aim of the present study was to compare the
clinical effectiveness of ABA versus a subsequent
anti-TNF agent among RA patients with previous
anti-TNF exposure in a large US cohort of RA
Harrold LR, et al. Ann Rheum Dis 2013;0:1–7. doi:10.1136/annrheumdis-2013-203936 1
Clinical and epidemiological research
 ARD Online First, published on January 29, 2014 as 10.1136/annrheumdis-2013-203936
Copyright Article author (or their employer) 2014. Produced by BMJ Publishing Group Ltd (& EULAR) under licence. 
 group.bmj.com on March 24, 2014 - Published by ard.bmj.comDownloaded from 
patients using the Consortium of Rheumatology Researchers of
North America (CORRONA) registry. Speciﬁcally, we sought to
compare change in disease activity, composite response rates,
meaningful improvement in function and remission outcomes
over a 1-year period.
METHODS
Data sources and data collection
CORRONA is a US observational cohort of patients with arth-
ritis who are enrolled by participating rheumatologists in 132
practices both academic and private practice with prospective
data collection; the details have been previously described.16 17
Data are collected from both patients and their treating rheuma-
tologists, who gather information on disease duration, progno-
sis, disease severity and activity, medical comorbidities, use of
medications including DMARDs and adverse events.18
Laboratory data such as inﬂammatory markers are not available
at all visits as they are not mandated due to the observational
nature of the registry and some rheumatologists do not obtain
this information routinely. Follow-up assessments are requested
at least as often as every 4 months and completed during
routine clinical encounters. Approvals for participation in the
CORRONA registry are obtained from respective Institutional
Review Boards (IRBs) of participating academic sites and a
central IRB for private practice sites, and patients provide
informed consent before enrolment.
Study population
There were 27 412 patients with a diagnosis of RA in the regis-
try. We identiﬁed patients with exposure to one or more
anti-TNF agents but no prior use of non-anti-TNF biologics
using CORRONA data between 2/1/2000 and 8/1/2011. For the
main analyses, we included all patients regardless of reason for
the switch to ABA or a subsequent anti-TNF following prior
exposure to an anti-TNF. However, in the sensitivity analyses,
we included those patients who were inadequate responders to
the prior anti-TNF. Inclusion criteria into the study cohort
included receipt of either a subsequent anti-TNF or ABA, a
follow-up appointment at 6 and/or 12 months following initi-
ation and the presence of all the elements necessary to calculate
response based on the Clinical Disease Activity Index (CDAI), a
well-recognised instrument to measure disease activity, and
ACR20, 50 and 70 responses.19–21 For the purpose of this
study, RA patients in remission at baseline, meaning at the time
the new agent was initiated, deﬁned by CDAI ≤2.8, were
excluded from the study population (switching while in remis-
sion is seen when cost or tolerability inﬂuences medication use).
Measures and data collection
Data were collected during the study period from physician
assessment and patient questionnaires completed during clinical
encounters. Non-biologic and biologic DMARDs, including
anti-TNF agents, are recorded at the time of the clinical encoun-
ter. Among the data elements collected in the registry relevant
to this study are a 28 tender and swollen joint count, physician’s
and patient’s global assessments of disease activity, patient’s
assessment of pain, the modiﬁed Health Assessment
Questionnaire (mHAQ) assessing physical function and erythro-
cyte sedimentation rate (ESR). When available, acute phase
reactant data are recorded from laboratory tests obtained within
10 days of the clinical encounter.
Study outcomes
Responsiveness to medication treatment was deﬁned based on
improvement in CDAI as our primary outcome (eg, baseline
CDAI—follow-up CDAI). As a secondary outcome, we evalu-
ated modiﬁed ACR20 (mACR20), modiﬁed ACR50 (mACR50)
and modiﬁed ACR70 (mACR70) responses, which do not
include acute phase reactants. These measures have been previ-
ously deﬁned and validated and shown to highly correlate with
ACR responses that include acute phase reactants.20 22 An
mACR20 response required ≥20% improvement in tender joint
count and swollen joint count, as well as two or more of the
four remaining ACR response components, including physician’s
global assessment, patient’s global assessment, patient’s global
pain and mHAQ. The mACR50 and mACR70 responses were
calculated using the same criteria requiring 50% and 70%
improvement, respectively. In addition, we evaluated achieve-
ment of a clinically meaningful change in the mHAQ (≥0.25).23
Disease remission outcomes were deﬁned using CDAI.
As sensitivity analyses, we examined improvement in the
modiﬁed Disease Activity Score 28 (mDAS28), which is calcu-
lated without results of acute phase reactants as well as achieve-
ment of remission using the mDAS28 cut-off of <2.6 (eg,
baseline mDAS—follow-up mDAS).24 25 Speciﬁcally, the predic-
tors of the ESR include tender and swollen 28 joint counts,
patient’s and physician’s global assessments, patient’s pain
assessment and physical function (mHAQ). The calculation of
the mDAS28 is shown as follows:
mDAS28 ¼ 0:53
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ð28TJCÞ
p
þ 0:31
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ð28SJCÞ
p
þ 0:25mHAQþ 0:001 PAINþ 0:005
 EGAþ 0:014 PGAþ 1:694
It has been previously shown that the mDAS28 performs as well
as the DAS28 as a measure of response and disease activity.25
Potential confounders
Given concerns regarding treatment-selection bias, we used pro-
pensity score (PS) matching. A PS is the predictive probability of
an outcome; in this case receiving ABA versus another anti-TNF.
PS matching has been used in numerous studies to reduce selec-
tion bias in observational studies.26 In this study, the PS was esti-
mated using a multivariable logistic regression model predicting
the use of ABA versus an anti-TNF using the following key vari-
ables: age, number of prior anti-TNF agents (one prior vs two
or more priors), duration of RA, swollen joint count, patient’s
global assessment, physician’s global assessment and insurance
type. We then matched on the PS (up to 1:4 match using a calli-
per of 0.01) using a greedy matching routine without replace-
ment.27 We matched separately patients who had a follow-up at
6 months as well as those with a follow-up at 12 months.
Patients could have contributed data to both groups. In addition,
matching was done based on the number of available patients.
Thus, for some analyses, up to four anti-TNF users were
matched to one ABA user while for other analyses it was four
ABA users to one anti-TNF users. Initially we performed the
analyses based on prior anti-TNF use, speciﬁcally comparing PS
matched ABA and anti-TNF users exposed to only one prior
anti-TNF separately from PS-matched ABA and anti-TNF users
exposed to two or more anti-TNFs. However, the results were
not different; so we pooled the groups together.
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Statistical analysis
Patient clinical and demographic characteristics were compared
within the two matched cohorts (6 and 12 months). For con-
tinuous measures, means and SDs were estimated and t tests
were used to test statistical differences among the groups. For
dichotomous measures, percentages were estimated and Fisher’s
exact test was used to test statistical differences among the
groups. Response outcomes were deﬁned based on the change
in CDAI, change in mDAS28 as well as mACR20, mACR50 and
mACR70 responses and meaningful change in mHAQ as
deﬁned above. Remission outcomes were based on CDAI and
mDAS28. For patients who discontinued ABA or the subsequent
anti-TNF agent, the last observation prior to the discontinuation
was carried forward.
Comparisons of response rates were made at 6 and
12 months postinitiation using 3-month time windows for cap-
turing study visits. For patients with two or more visits within
the window, we used the visits closest to the date of interest
(6 or 12 months). Weighted mean improvement and response
rates for both time points were estimated. Unadjusted and
adjusted estimates comparing differences (for CDAI and
mDAS28), response rates (mACR20, mACR50 and mACR70),
meaningful improvement in function (mHAQ) and remission
rates (CDAI and mDAS28) were performed separately using
generalised linear latent and mixed models (GLLAMM). We
used GLLAMM because we needed two levels of weights due to
the n:1 matching and hierarchical nature of the data (eg,
patients nested by physician) as these factors have been shown
to inﬂuence the evaluations of treatment effectiveness.
Speciﬁcally, we included multilevel weights and clustering on
physician. The ﬁrst level is for the patient with individual
weights based on the PS matching ratio, and the second level is
for the physician. We computed the second-level weights by
averaging the individual probability weights within each phys-
ician. These results were reported with estimated 95% CIs.
Residual differences in baseline characteristics after matching
were included in the outcome models. Patients with missing
data for any of the variables in the ﬁnal models were excluded
from the models. Additionally, we explored potential interac-
tions between medication selection (ABA vs anti-TNF) and
number of prior anti-TNF agents in the models.
Additional sensitivity analyses were carried out, which
included re-running the analyses with 1:1 matching. To assess
whether responses differed based on previous experience with
an anti-TNF, we re-ran the analyses (both 1:n and 1:1 matching
approaches) restricting it to patients who had an inadequate
clinical response to the prior anti-TNF; speciﬁcally we excluded
patients who switched for safety, tolerability or other reasons
from this sensitivity analysis. All analyses were conducted using
STATAV.10 and 11.
RESULTS
There were 3076 RA patients who met inclusion and exclusion
criteria including prior exposure to one or more anti-TNFs, ini-
tiation of either of ABA (n=968) or a subsequent anti-TNF
(n=2108) without prior use of a non-TNF biologic (ﬁgure 1).
Among those with a follow-up appointment at 6 months follow-
ing initiation, there were 440 ABA users and 958 anti-TNF
users. Propensity matching was performed for those with a
6-month follow-up appointment, resulting in 431 ABA and 746
anti-TNF users of which 66% had been exposed to only one
prior anti-TNF (table 1). After matching there was better
balance across most baseline patient characteristics; however,
there was still imbalance across several covariates, including
medicare insurance, rheumatoid factor seropositivity, disease
duration, mHAQ and concomitant prednisone use, which were
added as individual covariates to the outcome models. For
follow-up at 12 months, there were 327 ABA users and 637
anti-TNF users. Those with follow-up at 12 months were PS
matched, resulting in 311 ABA users and 493 anti-TNF users of
Figure 1 Selection of the study
cohorts.
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whom 68% had exposure to only one prior anti-TNF and there
was good balance across most baseline characteristics except for
disease duration that was added to as an individual covariate to
the outcome models (see online supplementary table for the
cohort with follow-up at 12 months). There were 272 ABA
users and 531 anti-TNF users who contributed to both the
6-month and 12-month cohorts.
Among the ABA users, 21.5% discontinued the medication by
6 months, and by 12 months it was 27.6%. In anti-TNF users,
36.6% discontinued the medication by 6 months and 38.2% by
12 months. Among those who discontinued, toxicity was
reported by 5.6% of ABA users by 6 months and 3.0% by
12 months. For anti-TNF users, it was 13.0% by 6 months and
9.0% by 12 months.
At 6 months, response rates based on mean change in CDAI
were similar in ABA users as compared with anti-TNF users
(−6.1 vs −5.6) in both unadjusted and adjusted analyses (ﬁgure 2).
Achievement of a mACR20 occurred in 31.7% of ABA users
and 28.2% of anti-TNF users, which was not signiﬁcant in
unadjusted or adjusted analyses. Achievement of a mACR50 was
more likely in ABA users as compared with anti-TNF users
(19.7% vs 14.5%; adjusted OR of 1.40; 95% CI 1.05 to 1.85).
The mACR70 response rates were similar, occurring in 8.6% of
ABA users and 6.8% of anti-TNF users, which were not signiﬁ-
cantly different in both unadjusted and adjusted analyses.
Achievement of a clinically meaningful improvement in mHAQ
was similar, occurring in 33.1% of ABA users and 30.2% of
anti-TNF users. At 12 months, response rates based on change
in CDAI seemed to favour anti-TNF users with borderline sig-
niﬁcance (difference in mean change of CDAI of −1.64; 95%
CI −3.47 to 0.19). Between 35% and 37% of both groups
achieved a mACR20, 20–22% a mACR50 and 10–12% a
mACR70; none of these differences were signiﬁcant in
unadjusted or adjusted analyses. Achievement of a meaningful
clinical improvement in function occurred similarly in the two
groups (28.9% of ABA users and 29.8% of anti-TNF users).
Remission rates based on CDAI were similar at 6 months, occur-
ring in 9% of ABA users and 10% of anti-TNF users (ﬁgure 3).
At 12 months, remission rates were 12–14% among both
groups based on CDAI.
Results were similar when using the change in mDAS28 (0.81
vs 0.68; p=0.13) at 6 and 12 months (1.03 vs 1.03; p=0.93).
Achievement of mDAS28 remission occurred more often in
ABA users (20.2% vs 17.3%) at 6 months, which was signiﬁcant
in adjusted analyses (OR 1.55; 95% CI 1.01 to 2.36). To
further explore whether outcomes in the two groups differed
based on response to the prior anti-TNF, we re-ran the analyses
in those patients who discontinued their prior anti-TNF due to
lack of efﬁcacy and similar results were found (see online sup-
plementary ﬁgures). Additionally, we explored the robustness of
our results using two strategies to ensure our matching protocol
did not inﬂuence the ﬁndings. First, we redid the analyses using
1:1 matching as well as evaluating the 6-month and 12-month
outcomes in a single cohort of patients who were seen both at
6 and 12 months. Again, the results were similar to those found
with the 1:n matched cohort presented here.
Table 1 Baseline characteristics of unmatched and matched cohorts using abatacept or an anti-TNF with follow-up at 6 months
Unmatched Matched
ABA
(N=440)
Anti-TNF
(N=958) p Value
ABA
(N=431)
Anti-TNF
(N=746) p Value
Demographics
Age (mean age, SD) 57.7 (12.4) 55.6 (12.5) 0.003 57.6 (12.4) 57.2 (11.7) 0.578
Gender (% female) 82.7 80.0 0.242 82.4 79.1 0.196
Race (% white) 81.8 85.4 0.097 82.4 85.1 0.216
Insurance (%)
Private 78.6 79.3 0.830 79.4 81.0 0.542
Medicare 36.8 29.8 0.012 36.4 30.8 0.053
Medicaid 5.0 6.9 0.188 5.1 6.4 0.374
Clinical
Rheumatoid factor seropositivity (%) 71.3 78.0 0.032 70.7 80.0 0.006
Disease duration (mean years, SD) 13.4 (10.3) 11.5 (9.4) 0.000 13.3 (10.0) 12.1 (9.8) 0.045
Tender joints, N (SD) 7.4 (7.1) 7.3 (7.1) 0.717 7.4 (7.1) 7.3 (7.1) 0.811
Swollen joints, N (SD) 6.8 (6.0) 5.9 (5.3) 0.005 6.7 (5.9) 6.1 (5.2) 0.087
Patient pain score (mean, SD) 52.7 (25.3) 49.3 (25.8) 0.023 52.7 (25.5) 50.2 (25.8) 0.112
mHAQ (mean, SD) 0.7 (0.5) 0.6 (0.5) 0.012 0.7 (0.5) 0.6 (0.5) 0.047
CDAI (mean, SD) 22.9 (14.1) 21.4 (13.2) 0.057 22.8 (14.1) 21.7 (12.9) 0.182
Disease activity* (%) 0.210 0.354
Low 19.8 20.6 20.2 19.0
Moderate 35.7 39.8 35.7 40.0
High 44.6 39.7 44.1 41.0
Concomitant medications
Corticosteroids, (%) 40.0 34.0 0.036 39.4 33.0 0.027
Leflunomide, (%) 12.5 12.7 0.931 12.5 13.3 0.787
MTX, (%) 54.8 57.1 0.417 55.2 55.5 0.951
Dose, mg/week (SD) 16.3 (6.2) 16.4 (6.0) 0.843 16.3 (6.2) 16.2 (5.9) 0.906
ABA, abatacept; anti-TNF, anti-tumour necrosis factor; CDAI, Clinical Disease Activity Index; mHAQ, modified Health Assessment Questionnaire; MTX, methotrexate.
*Disease activity based on the CDAI.
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DISCUSSION
Using data from CORRONA, a large US-based RA registry, we
compared the clinical effectiveness of ABA versus a subsequent
anti-TNF agent among RA patients with previous anti-TNF
exposure. Speciﬁcally, we compared change in disease activity
and remission rates based on CDAI and mDAS28 as well as
ACR response rates and meaningful improvement in function.
Both treatments were effective for the primary outcome of inter-
est as the minimally clinically important difference for change in
CDAI is 4.3.20 We examined effectiveness based on several dif-
ferent outcome measures (change in disease activity, mACR
response, meaningful improvement in mHAQ and remission)
and timeframe. For the vast majority of the analyses, effective-
ness was similar in the two treatment arms. This is further sup-
ported by our sensitivity analysis in which we limited the
sample to those who discontinued their prior anti-TNF due to
lack of efﬁcacy and found similar results.
While our results stem from an observational cohort, they are
similar to two recent systematic reviews based on clinical trials
that compared the efﬁcacy of ABA with other biologic agents
using Bayesian network meta-analysis methods9 28 in inadequate
responders to MTX. In the ﬁrst review, ABA was compared with
TNF and non-TNF biologics and found to have similar ACR50
and remission rates9 at 24 and 52 weeks. In the second review,
ABA was compared with anti-TNF agents with similar responses
to therapy found based on change in HAQ and ACR response
rates at 6 months.28 A recently published systematic review of
randomised clinical trials in patients with inadequate response
to nbDMARDs found that use of ABA as compared with
anti-TNFs was associated with equivalent ACR20 and ACR50
responses at 6 and 12 months, but there was a higher likelihood
of achieving an ACR70 response and DAS28 remission at
12 months with ABA.29 In contrast, a meta-analysis of
randomised clinical trials of patients with inadequate
response to MTX suggested a higher probability of achieving
an ACR50 response with anti-TNFs as compared with ABA.8
These differences may in part be related to different time
periods for the selection of relevant studies and analysis techni-
ques. In a recent head-to-head comparison of the addition of
ABA versus adalimumab in biologic-naïve patients on back-
ground MTX, no meaningful differences in efﬁcacy were
found.14 Additionally, ABA has been compared with anti-TNF
agents in the MTX-naïve early RA population with no differ-
ences in time to response and response achieved over a 1-year
time period.30 31 Our ﬁndings complement these studies as
according to our knowledge it is the ﬁrst study that examines
comparative effectiveness in those with prior exposure to
anti-TNF.
Figure 2 Adjusted* response rates at
6 and 12 months among abatacept
and anti-tumour necrosis factor
(anti-TNF) users. *Adjusted for number
of prior anti-TNF medications, baseline
disease activity, rheumatoid arthritis
disease severity and concomitant
medications. Adjusted mean difference
in Clinical Disease Activity Index
(CDAI) at 6 months was 0.46 (95% CI
−0.82 to 1.73) and at 12 months –
1.64 (95% CI −3.47 to 0.19). Adjusted
OR for modiﬁed American College of
Rheumatology (mACR)20 response at
6 months was 1.05 (95% CI 0.81 to
1.36) and at 12 months 0.87 (95% CI
0.59 to 1.29). Adjusted OR for
mACR50 response at 6 months was
1.40 (95% CI 1.05 to 1.85) and at
12 months 0.86 (95% CI 0.58 to 1.27).
Adjusted OR for mACR70 response at
6 months was 1.72 (95% CI 0.84 to
3.53) and at 12 months 1.12 (95% CI
0.56 to 2.24). Adjusted OR for
meaningful change in modiﬁed Health
Assessment Questionnaire (mHAQ) at
6 months was 1.15 (95% CI 0.86 to
1.54) and at 12 months 0.74 (95% CI
0.48 to 1.15).
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Currently, it is not possible to predict which patients will
respond to which particular biologic agent. However, this study
suggests that just changing the mechanism of action may not be
enough to improve disease activity. When discussing next thera-
peutic interventions in those not responding or unable to take
their current anti-TNF agent, these results can potentially con-
tribute to the discussion as patient weigh other factors such
potential adverse events associated with the different agents,
out-of pocket costs and medication route of administration that
impacts convenience. The current availability of ABA as an
intravenous infusion and subcutaneous injection does allow
more ﬂexibility for the patient’s preference.
Our study has several strengths. We utilised a national
US-based registry of RA patients with physician-derived
outcome measures to examine comparative effectiveness in
patients with prior anti-TNF exposure. We examined drug
response (based on change in disease activity, achievement of a
modiﬁed ACR response and achievement of a meaningful
improvement in mHAQ) and remission. In addition, we used
both CDAI and mDAS28 to assess response and remission. This
work focused on the real-world’ effectiveness of agents in US
patients, who are markedly different than RCT subjects in terms
of comorbidities and RA disease activity, and more representa-
tive of patients found in clinical practice.32 Finally, we were able
to use advanced epidemiologic methods (eg, PSs) to compare
responses to the different agents when selection bias exists.
However, there are limitations to our study. The timing of the
study visits was based upon clinic visits and not mandated as
occurs in RCTs that inﬂuenced which patients were included
based on follow-up visits. Of note, the mean study interval
between study visits was approximately 4.5 months. Most of the
patients were white, which limits generalisability to other racial
groups. In addition, acute phase reactant data were not available
for all patients in the study. As a result, we applied previously
validated outcome measures not requiring acute phase reactants
such as CDAI and mDAS for response and remission outcomes as
well as modiﬁed ACR response rates and mHAQ scores.20 22 25
While PS matching improved the balance between the cohorts to
most measure covariates, it is possible that there is still residual
confounding for unmeasured covariates.
In summary, the results of this US-based observational study
indicate similar rates of drug response and remission with use of
ABA and anti-TNF agents among those with prior anti-TNF
exposure. These ﬁndings were unchanged when we limited the
analyses to those who failed their prior anti-TNF due to lack of
efﬁcacy. While we saw no difference when comparing ABA with
anti-TNF agents, other non-TNF biologics with different
mechanisms of action may be associated with superior outcomes
as compared with anti-TNFs . Further comparative effectiveness
studies are necessary to evaluate the beneﬁts of switching to a
different non-TNF biologic versus anti-TNF intraclass switching
among patients with an inadequate response to an anti-TNF.
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